Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.
Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
Altamira is actively engaged in three primary areas:
- RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
- Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
- Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.
Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.
In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.
Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.
Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.
Altamira Therapeutics (NASDAQ:CYTO) announced promising results from three clinical studies of its nasal spray, Bentrio, targeting allergic rhinitis. Notably, a study on house dust mites revealed a statistically significant reduction in symptoms, while a grass pollen study demonstrated a faster onset of action and better efficacy ratings. Bentrio also exhibited superior distribution in the nasal cavity, providing longer-lasting protection compared to saline spray. These findings will be presented at the 2023 AAAAI Annual Meeting on February 25, 2023, highlighting the spray's effectiveness and safety in managing allergic responses.
Altamira Therapeutics (NASDAQ:CYTO) announced its participation in the 14th Annual RNA Therapeutics Conference in London (February 8-9) and the 4th Annual RNAi Based Therapeutics Summit in Boston (March 21-23, 2023). Key presentations will be delivered by Dr. Covadonga Pañeda and Dr. Samuel A. Wickline, focusing on the company's innovative platforms, OligoPhore and SemaPhore, which enhance the delivery of siRNA to extrahepatic targets, differentiating from traditional lipid-based solutions. The firm is advancing its flagship siRNA programs targeting KRAS-driven cancers and rheumatoid arthritis, leveraging its robust nucleic acid delivery system.
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has provided a strategic update on its business, highlighting ongoing efforts to divest legacy assets and advances in its therapeutic pipeline. The company is in decisive discussions with OTC consumer health firms for Bentrio marketing partnerships, bolstered by promising data from the NASAR study on allergic rhinitis. Despite inconclusive results from the COVAMID study, Bentrio's preventive efficacy against viral infections remains supported by positive data. Additionally, a restructuring of a CHF 5 million convertible loan has been agreed upon to enhance financial flexibility, while leadership changes have been made to focus on RNA delivery.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced significant interim results from its NASAR trial for Bentrio® in seasonal allergic rhinitis, revealing a 1.55-point reduction in nasal symptoms compared to saline, p=0.015. The main trial phase is completed, with full results expected in Q2 2023. Additionally, top-line data from the COVAMID trial showed a trend for better nasal viral load reduction in COVID-19 patients receiving Bentrio, though key endpoints were not met. The company emphasizes the potential market for non-medicated allergy treatments could reach nearly $4 billion in sales in the US in 2023.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that COO Dr. Covadonga Pañeda will present at the 2nd Annual mRNA-Based Therapeutics Summit Europe in Berlin from January 24-26, 2023. Dr. Pañeda's presentation will focus on the SemaPhore™ platform, highlighting its advantages for extrahepatic mRNA delivery compared to traditional liver-restricted methods. Altamira aims to enhance protein production outside the liver using mRNA, addressing unmet medical needs. The mRNA therapeutic field is rapidly evolving, with Altamira at the forefront of this innovation.
Altamira Therapeutics (NASDAQ:CYTO) provided a business update highlighting its strategic repositioning to focus on RNA delivery. The company is actively seeking partners for its Bentrio product following recent FDA clearance. A divestiture process for inner ear therapeutics is ongoing, with a cash consideration of $2.2 million expected. CEO Thomas Meyer emphasized a committed transformation and the promotion of Covadonga Pañeda to COO to enhance operational focus. Upcoming data from clinical trials for Bentrio in COVID-19 and allergic rhinitis is anticipated in early 2023.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced progress in its clinical trial for Bentrio, reaching the midpoint of 50 patients enrolled in the NASAR trial for Seasonal Allergic Rhinitis (SAR). An interim analysis confirmed the target enrollment of 100 patients, with completion expected by early January 2023.
The trial compares Bentrio's efficacy against saline nasal spray, aiming to measure the reflective Total Nasal Symptom Score. Top-line data is anticipated in late Q1 2023, highlighting the potential of Bentrio as a drug-free treatment for allergic rhinitis.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) reported significant updates on its Bentrio nasal spray and RNA delivery technologies. Bentrio was launched in Hong Kong, with potential expansion to North America and Europe anticipated by year-end. A divestiture of inner ear assets is expected to close in December, potentially bringing in $27 million. Financially, Altamira recorded revenues of CHF 1.2 million for H1 2022, but incurred a net loss of CHF 7.3 million. The company expects cash needs between CHF 22-25 million through 2023 while focusing on RNA therapeutics development.
Altamira Therapeutics (NASDAQ: CYTO) announced that its partner, Nuance Pharma, has launched the Bentrio nasal spray in Hong Kong, targeting a population of 7.3 million. This is the first move into the Chinese market, with plans to file for marketing approval in Mainland China, Macao, and South Korea in 2023. Altamira received an upfront payment of $1 million and could earn up to $22.5 million in additional milestones. Bentrio aims to protect against airborne viruses and allergens, which is particularly relevant given ongoing COVID-19 concerns in densely populated areas.
Altamira Therapeutics (NASDAQ:CYTO) announced that animal study data presented at the American Heart Association Annual Scientific Sessions 2022 demonstrated effective delivery of SOD2 mRNA using its SemaPhore technology. The research showed significant improvements in mitochondrial protection and plaque stability in atherosclerosis models. Following treatment, mice exhibited a 25% reduction in inflammatory macrophages and a 98% increase in smooth muscle cells, indicating less plaque vulnerability. This highlights the potential of nanoparticle-based mRNA therapeutics in addressing atherosclerosis complications.
FAQ
What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What areas of therapeutics does Altamira Therapeutics focus on?
What are the main products of Altamira Therapeutics?
Where is Altamira Therapeutics headquartered?
What is the stock symbol for Altamira Therapeutics?
What recent achievements has Altamira Therapeutics made in RNA therapeutics?
What stage are the inner ear disorder treatments in?
How does the OligoPhore™ platform work?
What are the recent clinical trial results for Bentrio™?
What is the significance of recent financial reclassifications for Altamira?
How can investors stay updated with Altamira Therapeutics?
